INTRODUCTION
flow diversion therapy is that when a high metal density (low porosity) stent is placed across the aneurysm neck, it induces 1) a change in the direction of blood flow away from the target aneurysm sac toward the distal parent artery, and stasis of blood in the sac resulting in intraaneurysmal thrombosis, and 2) an acceleration of the neointima formation along the dense stent struts across the aneurysm neck. The combination of these effects can kjronline.org result in the exclusion of the aneurysm from circulation, and ultimately, aneurysm shrinkage. Since the introduction of flow diverters, a growing body of evidence has shown that they are more durable, and as a result, there has been a rapid increase in their use to treat aneurysms (3) (4) (5) (6) .
Recently, we reported that a newly-developed flow diverter (FloWise; Taewoong Medical, Seoul, Korea) was effective for aneurysm occlusion when evaluated in an elastase-induced rabbit aneurysm model ( Fig. 1) (7) . Here, we report the results of a single-center, prospective pilot study with a small number of human subjects. The aim of this pilot clinical study was to evaluate the safety and efficacy of the FloWise flow diverter.
MATERIALS AND METHODS
This study was approved by the Institutional Review Board, and written informed consent was obtained from every patient before enrollment in the study. Verbal explanations were given to both the patient, and at least one first-degree relative twice, and written informed consent was obtained by the primary investigator.
This study was conducted as a single-center, pilot clinical study to evaluate the safety and efficacy of FloWise in a small population (n = 10) prior to launching a large, multicenter prospective study. Inclusion criteria were as follows: 1) 18-75 years of age, 2) pre-treatment modified Rankin scale score (mRS) of 0-2, 3) unruptured internal carotid artery (ICA) aneurysm with a dome diameter ≥ 8 mm and a neck diameter ≥ 4 mm, or 2 or more unruptured ICA aneurysms able to be spanned by a single FloWise, and 4) written informed consent. Exclusion criteria were as follows: 1) currently pregnant, 2) intracranial hemorrhage within the last 30 days, 3) untreated aneurysm that had ruptured within the last 30 days, 4) any contraindication for antiplatelet medication use, 5) major surgery within 30 days of the treatment, 6) a platelet count of less than 100000, 7) untreated cancer or immunocompromising disease, 8) serum creatinine levels of more than 2.5 mg/dL, 9) a previously inserted stent in the parent artery harboring the target aneurysm, 10) nitinol allergy, 11) uncontrolled hypersensitivity to iodine contrast material, 12) active infection, and 13) a life expectancy of less than 5 years. Ten patients (all women; median age, 56 years; age range, 28-72 years) harboring 14 ICA aneurysms (median size, 9.4 mm; range, 2.3-31.0 mm; median neck diameter, 7.1 mm; neck diameter range, 2.0-10.2 mm) were enrolled between January 2016 and July 2017.
Antiplatelet Medication
All enrolled patients received dual antiplatelet medication (100 mg aspirin with 75 mg clopidogrel) for at least 5 days before treatment. An antiplatelet drug resistance test was obtained 1 day before treatment. If the antiplatelet resistance test was positive, an antiplatelet drug with a different mechanism of action was added. After completion of the treatment, dual antiplatelet medication was continued for 6 months, and then replaced by aspirin monotherapy.
The Flowise Flow Diverter
The specifications of the FloWise stent and the in vivo experimental results in a rabbit aneurysm model have been previously reported (7) . Briefly, the FloWise flow diverter stent is composed of a braiding of 48 strands of 0.0012-inch nitinol and platinum wires. These 48 strands are braided and heat-treated in the expanded configuration. After deployment from the delivery system, the FloWise expands to cover the neck of the aneurysm, forming a high-coverage mesh of approximately 33-41% by area, with a radioopacity similar to that of the Pipeline Flex (Medtronic, CA, USA) embolization device (Fig. 1A) . The FloWise is attached to a flexible delivery wire, which has radio-opaque end markers, and is packaged in an introducer sheath. The distal tip of the delivery wire is pre-shaped to a J shape (Fig. 1B) . The stent-contact portion of the delivery wire is coated with silicon so that it grips the FloWise, which allows for re-sheathing at any point prior to 70% deployment (Fig.  1C) . This packaged device can be loaded into standard microcatheters with at least a 0.027-inch inner diameter. It is pushed through the microcatheter and deployed by a combination of microcatheter withdrawal and forward pressure on the delivery wire. The FloWise undergoes approximately 38% shortening when deployed completely. The FloWise is available in 3.0, 3.5, 4.0, 4.5, and 5.0 mm in diameter, and 20, 25, 30, 35, and 40 mm in length.
Implantation of the Flowise Flow Diverter
All patients were treated under general anesthesia. kjronline.org inch microcatheter was navigated up to the ipsilateral middle cerebral artery M2 or M3 segment using a 0.014-inch microwire. Then, a FloWise stent that matched the largest diameter of the parent artery was introduced into the microcatheter and deployed, completely spanning the aneurysm neck. After deployment of the FloWise, followup angiograms were obtained at least two times each for 10 minutes. If enough flow diversion (shift of inflow zone from aneurysm distal neck to proximal neck and disruption of inflow jet), as judged by an experienced operator, was not seen after the first FloWise had been successfully implanted, an additional FloWise was inserted in an overlapping manner. If an acute in-stent thrombosis was detected, glycoprotein IIb/IIIa inhibitor (tirofiban, 0.5-1.0 mg) was intra-arterially administered and maintained for 12 hours after completion of the procedure.
Clinical and Imaging Follow Up
Outpatient based clinical follow-up was scheduled at one and three months post procedure. A computed tomography (CT) angiogram was obtained at the 3-month follow-up. The patient was then scheduled for readmission at 6 months ± 2 weeks for follow-up angiography. A data safety monitoring board (DSMB) was organized in order to maintain patient safety. The DSMB was independently composed of two physicians who were not working in the study hospital. During the clinical follow-up, telephone and e-mail contact with a clinical research assistant was possible at any time. If the patient complained of any symptom potentially related to the treatment, it was reported to the primary investigator as soon as possible. Complaints were recorded and the DSMB evaluated whether or not they were related to the treatment. Retreatment was planned in the event that, at the 6-month follow-up angiogram, the target aneurysm was found to be enlarged, causing any new neurological symptoms.
Primary and Secondary Endpoints
Co-primary endpoints included the rate of technical success, and a 50% or greater decrease in aneurysm sac volume at the 6-month follow-up angiogram. Technical success was defined as whether FloWise completely covered the neck of the target aneurysm. The secondary endpoint was the rate of complete occlusion at the 6-month follow- The primary safety endpoint was the development of a new neurological morbidity (defined by an mRS score ≥ 3) that persisted for more than 1 month post-treatment. Secondary safety endpoints were the development of new symptomatic ipsilateral ischemic stroke ≥ 5 on the National Institute of Health Stroke Scale, and an in-stent stenosis of more than 50% at the 6-month follow-up angiogram.
Statistical Analysis
Statistical analysis was performed using IBM SPSS version 20 (IBM Corp., Armonk, NY, USA). Continuous variables are presented as the mean ± standard deviation, and categorical variables as numbers and percentages. The rates of primary and secondary end points were assessed at 6 months and presented as numbers and percentages.
RESULTS
FloWise placement was successful in all 10 patients. Eight patients were treated with a single FloWise stent, one patient was treated with two, and one patient was treated with three overlapping FloWise stents in order to obtain more flow diversion. Table 1 summarizes patient and aneurysm characteristics and 6-month follow-up results.
No new neurological deficits developed during the 6-month clinical follow-up period. Nine patients with 12 aneurysms received 6 months of angiographic followup. One patient did not receive follow-up imaging due to pregnancy. One patient was retreated with Pipeline Flex due to lack of change in aneurysm volume, and progressive mass symptom aggravation. The patient's symptoms resolved completely after 1 month of retreatment and resulted in complete occlusion of the aneurysm 6 months posttreatment. Ten aneurysms (83.3%) showed a 50% or more decrease in volume (mean volume decrease, 82.8 ± 32.9%) of which 8 (66.7%, 95% confidence interval, 35.4-98.0%) showed complete occlusion (Fig. 2) . One patient, who had three overlapping FloWise stents, showed asymptomatic instent stenosis ≥ 50% (Fig. 3) . At 12 months, 10 aneurysms (83.3%) showed complete occlusion.
DISCUSSION
In this pilot prospective clinical study, FloWise showed 1) no treatment-related complications, 2) an aneurysm volume decrease of 50% or more in 83.3% of the treated aneurysms at 6 months, and 3) complete occlusion of 66.7%, and 83.3% of target aneurysms at 6 months and 12 months, respectively.
Endovascular treatment is one of the standard treatments for intracranial aneurysms and has been shown to be superior to clipping in the majority of reports (1, 2, 8) . However, conventional endovascular coil embolization yields low complete occlusion rates and high recurrence rates, especially in wide-necked, large, and giant aneurysms kjronline.org (8) (9) (10) . With advanced techniques, such as a multi-catheter, balloon, stent assistance, or a combination of these techniques, most difficult aneurysms can be treated (11) (12) (13) (14) (15) (16) . However, advanced techniques require more technical demands, and, as a result, a number of complex or fusiform aneurysms remain uncoilable (3) . A treatment with multiple overlapping stents was initially developed for flow diversion therapy in dissecting, blister-like, or fusiform aneurysms and had shown promising results (17) (18) (19) (20) (21) (22) (23) (24) (25) . In addition, in vitro experimental studies showed a high probability of success when implementing flow diversion therapy for aneurysm treatment (26, 27) . Based on the results of clinical and experimental studies, flow diverter stents have been developed for the treatment of wide-necked, large, and giant aneurysms, which are difficult to treat with coiling (3, 28) . A growing body of evidence is available on the effectiveness of flow diverters for treating various types of aneurysms (3-6). There have been several commercially available flow diverters; Pipeline Flex, SILK (Balt Extrusion, Montmorency, France), Surpass Streamline (Stryker Neurovascular, Fremont, CA, USA), FRED (MicroventionTerumo). The characteristics of these flow diverters are summarized in Table 2 .
Until recently, there were several flow diverter types commercially available in Korea, and a multicenter experience was reported (29) . However, these flow diverters were quite expensive and required technical expertise. As a result, aneurysm treatment with commercially available kjronline.org kjronline.org flow diverters is very limited in Korea and has resulted in considerable one-month mortality rates (30) . We developed a new flow diverter that is easy to use and resheathable. It has a metal density of approximately 33-41%, depending on the relationship between the parent vessel and stent diameter, which is comparable to other commercially available flow diverters (31) . This pilot study was conducted to preliminarily evaluate the safety and effectiveness of the FloWise flow diverter before a prospective multicenter study. FloWise placement was successful in all patients, and there were no newlydeveloped neurological symptoms during the 6-month follow-up period. However, it has been reported in the literature that other commercially available flow diverters have shown combined major morbidity and neurological mortality rates of 5.6-7.7% (4, 5) . Due to the small sample size of this pilot study, it cannot be assumed that the FloWise flow diverter is safer than other commercially available flow diverters. One explanation for the absence of complication in this pilot study is that all procedures were done by a single operator who had extensive experience in commercially available flow diverters. Given that implantation of a flow diverter stent requires considerable technical expertise, placement by an experienced operator might be helpful to avoid periprocedural complications. Additionally, in cases that an operator judged flow diversion to be insufficient after implantation of the first FloWise, additional devices were overlapped until flow diversion appeared to be sufficient. In the authors' opinion, this may help to avoid delayed complications, such as aneurysm rupture. Complete occlusion was observed in 66.7% and 83.3% of target aneurysms at 6 months and 12 months, respectively, after FloWise implantation. These rates are comparable with the rates reported in the literature (55.7-93.3%) (32) . Although the sample size was small, the safety and effectiveness of FloWise did not appear to be inferior to the safety and effectiveness of commercially available flow diverters. If FloWise's safety and effectiveness is validated in a larger population, FloWise could be an additional tool for flow diversion therapy in intracranial aneurysms.
In conclusion, FloWise appears to be a safe and effective treatment for unruptured ICA aneurysms. A prospective multicenter study to validate the safety and effectiveness of the FloWise stent would be worthwhile. 
